Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CHRS

Coherus Oncology Inc

Feb 12 • 04:00PM ET

2.01

-0.03 -1.47 %

Healthcare • Biotechnology • USA • NASD

Feb 12, 9:25 PMCoherus Oncology prices underwritten public offering of 28.6M shares at $1.75 to raise approximately $50.1M, granting underwriters a 30-day option for an additional 4.29M (15%) shares, with proceeds to fund LOQTORZI commercialization, pipeline development, and general corporate purposes.

Peers: AMGN GILD ABBV VRTX REGN BIIB INCY BMRN NBIX EXEL

| Held by: IWM VTI VXF IWN SCHA VTWO IWO IWC PRFZ SCHB

Index	RUT	P/E	-	EPS (ttm)	-1.59	Insider Own	21.76%	Shs Outstand	116.24M	Perf Week	-3.83%
Market Cap	242.95M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	0.00%	Shs Float	94.57M	Perf Month	18.24%
Enterprise Value	105.61M	PEG	-	EPS next Q	-0.36	Inst Own	41.76%	Short Float	31.30%	Perf Quarter	48.89%
Income	-183.71M	P/S	2.91	EPS this Y	-714.73%	Inst Trans	0.78%	Short Ratio	16.07	Perf Half Y	101.20%
Sales	83.57M	P/B	2.66	EPS next Y	26.84%	ROA	-36.70%	Short Interest	29.60M	Perf YTD	41.55%
Book/sh	0.76	P/C	1.27	EPS next 5Y	-	ROE	-860.65%	52W High	2.62 -23.16%	Perf Year	79.46%
Cash/sh	1.59	P/FCF	-	EPS past 3/5Y	- -27.36%	ROIC	-130.94%	52W Low	0.71 183.10%	Perf 3Y	-73.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-6.50% -5.60%	Gross Margin	42.94%	Volatility	7.79% 9.99%	Perf 5Y	-88.93%
Dividend TTM	-	EV/Sales	1.26	EPS Y/Y TTM	-19972.15%	Oper. Margin	-201.91%	ATR (14)	0.18	Perf 10Y	-85.23%
Dividend Ex-Date	-	Quick Ratio	1.23	Sales Y/Y TTM	-72.54%	Profit Margin	-219.83%	RSI (14)	53.23	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.24	EPS Q/Q	-223.79%	SMA20	-1.12%	Beta	1.03	Target Price	6.75
Payout	0.00%	Debt/Eq	0.62	Sales Q/Q	-83.65%	SMA50	22.08%	Rel Volume	0.45	Prev Close	2.04
Employees	228	LT Debt/Eq	0.60	Earnings	Nov 06 AMC	SMA200	57.88%	Avg Volume	1.84M	Price	2.01
IPO	Nov 06, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.40% -13.41%	Trades		Volume	911,008	Change	-1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-23-26	Initiated	Oppenheimer	Outperform	$10
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral	$4 → $1.50
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15
Aug-08-17	Reiterated	JP Morgan	Overweight	$32 → $25

Show Previous Ratings

Feb-12-26 09:18PM	Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
05:20PM	Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates (Zacks)
04:05PM	Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire) +10.09%
Jan-16-26 08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
06:14AM	Loading…
Jan-14-26 06:14AM	Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? (Zacks) -5.88%
Jan-06-26 09:30AM	Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.56%
Jan-05-26 09:30AM	Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) (GlobeNewswire) +5.11%
Dec-08-25 08:30AM	Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma (GlobeNewswire) +6.67%
Nov-07-25 09:00AM	Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody (GlobeNewswire) -10.07%
12:09AM	Coherus Oncology Inc (CHRS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 08:15PM	Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:10PM	Coherus Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:14PM	Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
01:54PM	Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer (GlobeNewswire)
05:35PM	Loading…
Oct-30-25 05:35PM	Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates (Zacks)
08:30AM	Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-23-25 08:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-03-25 09:05AM	Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Sep-03-25 08:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.88%
Aug-08-25 08:18AM	Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences (Pharmaceutical Business Review) -7.13%
03:40AM	Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:30PM	Coherus Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:41PM	Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-06-25 06:10PM	Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 (Zacks)
10:29AM	Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA® (PR Newswire)
Jul-31-25 04:45PM	Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire) -6.64%
Jun-25-25 09:55AM	Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? (Zacks) -6.08%
Jun-06-25 04:29PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
08:00AM	Loading…
May-30-25 08:00AM	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics (GlobeNewswire)
May-27-25 08:30AM	Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI (toripalimab-tpzi) (GlobeNewswire)
May-13-25 02:22PM	Q1 2025 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) -19.11%
03:10AM	Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
May-12-25 05:30PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.30%
04:27PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:45AM	What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings (GuruFocus.com)
May-05-25 04:01PM	Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -7.27% -8.83%
May-01-25 05:04PM	Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:10AM	Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 (GlobeNewswire)
Apr-17-25 05:53AM	Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs (Seeking Alpha) +10.89%
Apr-15-25 09:44AM	Coherus divests Udenyca franchise to Intas for up to $558.4m (Pharmaceutical Technology) +8.76%
Apr-14-25 08:00AM	Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA Franchise (GlobeNewswire) +16.59%
Apr-01-25 08:00AM	Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes (GlobeNewswire)
Mar-25-25 04:30PM	Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -5.81%
Mar-21-25 07:10AM	Lazard Enhanced Opportunities Portfolio Q4 2024 Commentary (SeekingAlpha) +8.83%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 03:23PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey) -6.67%
Mar-11-25 01:46PM	Q4 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-10-25 04:32PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:12PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-25 07:06AM	What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings (GuruFocus.com)
Mar-03-25 08:30AM	Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 (GlobeNewswire) -9.46%
Feb-24-25 09:08AM	Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire) +7.48%
Feb-12-25 08:39AM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:00AM	Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 08:30AM	Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire) -8.19%
Dec-03-24 07:00AM	Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. (GlobeNewswire) +24.82%
06:06AM	Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M (BioPharma Dive)
Nov-27-24 04:01PM	Coherus Management to Participate in the 2024 Citi Global Healthcare Conference (GlobeNewswire)
Nov-07-24 01:09PM	Q3 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +13.29%
02:26AM	Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-06-24 05:15PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:08AM	Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +9.10%
Oct-30-24 04:20PM	Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-09-24 06:01PM	Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-28-24 07:24AM	Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:28AM	Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges (Insider Monkey)
Aug-08-24 05:50PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.85%
04:45PM	Coherus BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 09:00AM	Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire) -7.14%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
Jun-27-24 08:26AM	Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction (GlobeNewswire)
Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)
May-13-24 09:23AM	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating (MT Newswires) +10.00%
May-10-24 04:45PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.38%
May-09-24 05:15PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:30AM	Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan (GlobeNewswire)
May-08-24 09:00AM	Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer (GlobeNewswire)
May-01-24 04:30PM	Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +5.10% +5.34%
Apr-24-24 10:02AM	Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.34%
Apr-08-24 08:30AM	Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting (GlobeNewswire)
Mar-16-24 03:35PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:28PM	Why Coherus Biosciences Stock Tumbled on Thursday (Motley Fool) -5.65%
07:15AM	Q4 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:32PM	Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ... (GuruFocus.com)
04:13PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 (GlobeNewswire)

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wahlstrom Mats	Director	May 23 '25	Sale	0.74	99,988	73,881	0	May 28 05:12 PM

Open in Screener

TLSI

TriSalus Life Sciences Inc

Feb 12 • 04:00PM ET

4.77

-0.03 -0.63 %

Healthcare • Medical Devices • USA • NASD

TLSI TriSalus Life Sciences Inc daily Stock Chart

Peers: CRSP NTLA FATE IMTX EDIT BLUE SGMO ADAP CELU SLDB

| Held by: VTI IWM VXF VTWO IWN IWC IWO VTWV RSSL VTWG

Index	RUT	P/E	-	EPS (ttm)	-2.02	Insider Own	39.27%	Shs Outstand	49.89M	Perf Week	1.92%
Market Cap	238.33M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	0.00%	Shs Float	30.35M	Perf Month	-19.15%
Enterprise Value	249.76M	PEG	-	EPS next Q	-0.14	Inst Own	20.20%	Short Float	3.75%	Perf Quarter	9.91%
Income	-72.25M	P/S	5.93	EPS this Y	-35.73%	Inst Trans	9.20%	Short Ratio	6.87	Perf Half Y	20.76%
Sales	40.21M	P/B	-	EPS next Y	84.89%	ROA	-123.81%	Short Interest	1.14M	Perf YTD	-31.66%
Book/sh	-0.54	P/C	10.50	EPS next 5Y	-	ROE	-	52W High	7.95 -40.00%	Perf Year	-14.97%
Cash/sh	0.45	P/FCF	-	EPS past 3/5Y	- -175.42%	ROIC	-993.87%	52W Low	3.42 39.47%	Perf 3Y	-53.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	83.12%	Volatility	6.69% 6.49%	Perf 5Y	-53.78%
Dividend TTM	-	EV/Sales	6.21	EPS Y/Y TTM	19.34%	Oper. Margin	-77.74%	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	49.52%	Profit Margin	-179.71%	RSI (14)	37.41	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.05	EPS Q/Q	-693.54%	SMA20	-6.41%	Beta	0.43	Target Price	11.50
Payout	-	Debt/Eq	-	Sales Q/Q	57.38%	SMA50	-21.46%	Rel Volume	0.33	Prev Close	4.80
Employees	110	LT Debt/Eq	-	Earnings	Nov 13 AMC	SMA200	-8.35%	Avg Volume	165.73K	Price	4.77
IPO	Feb 08, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-546.03% -1.64%	Trades		Volume	55,029	Change	-0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-11-24	Initiated	ROTH MKM	Buy	$11
Oct-25-24	Initiated	Northland Capital	Outperform	$12.50
Sep-16-24	Initiated	Oppenheimer	Outperform	$10
May-30-24	Initiated	Canaccord Genuity	Buy	$12

Feb-09-26 09:00AM	TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors (Business Wire)
Jan-14-26 12:00PM	TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-12-26 07:00AM	TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance (Business Wire)
Dec-04-25 04:01PM	TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 (Business Wire) +5.37%
Nov-18-25 08:00AM	TriSalus Life Sciences Launches TriNav XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery (Business Wire)
12:04AM	Loading…
Nov-14-25 12:04AM	TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-13-25 05:15PM	TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance (Business Wire)
Nov-12-25 07:29AM	TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:10AM	Rockwell Medical (RMTI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-11-25 04:05PM	TriSalus Life Sciences to Participate in Upcoming Investor Conferences (Business Wire) +8.50%
Nov-10-25 08:00AM	TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025 (Business Wire) -8.88%
Nov-06-25 07:00PM	ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-05-25 06:15PM	biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.32%
Oct-30-25 08:00AM	TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call (Business Wire)
08:00AM	Loading…
Aug-28-25 08:00AM	TriSalus Life Sciences to Participate in Upcoming September Investor Conferences (Business Wire)
Aug-13-25 03:12AM	TriSalus Life Sciences Inc (TLSI) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.22%
Aug-12-25 05:10PM	TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance (Business Wire)
Aug-11-25 07:00PM	Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.62%
09:37AM	Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q2 2025 Result (GuruFocus.com)
08:00AM	TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique (Business Wire)
Aug-07-25 07:40AM	Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates (Zacks) -7.09%
Jul-30-25 04:05PM	TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Jul-29-25 04:05PM	TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call (Business Wire)
Jul-24-25 05:58PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock (Business Wire)
Jun-23-25 05:30PM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure (Business Wire) -5.37%
Jun-04-25 08:00AM	TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System (Business Wire)
May-30-25 07:00AM	TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience (Business Wire) -8.76%
May-16-25 03:01PM	TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
08:10AM	Loading…
May-15-25 08:10AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance (Business Wire)
May-12-25 07:15PM	OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised) (Zacks)
04:30PM	TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call (Business Wire)
07:45AM	OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-08-25 06:45PM	TerrAscend Corp. (TSNDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.31%
08:00AM	TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results (Business Wire)
Apr-10-25 11:33AM	VAREX IMAGING (VREX) Moves 16.5% Higher: Will This Strength Last? (Zacks)
Apr-09-25 08:47AM	TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Mar-30-25 08:02AM	TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks (Seeking Alpha)
Mar-27-25 02:02PM	TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:40AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 08:00AM	TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav Infusion System Mapping (Business Wire)
Mar-06-25 08:00AM	TriSalus Life Sciences Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model" (Business Wire)
Feb-03-25 04:05PM	TriSalus Life Sciences Announces Key Appointments to Board of Directors (Business Wire)
08:00AM	TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed (Business Wire)
Jan-23-25 08:00AM	TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call (Business Wire) +5.31%
Jan-10-25 08:30AM	TriSalus Life Sciences announces publication of pre-clinical data (TipRanks) +7.95%
Jan-09-25 08:00AM	TriSalus Life Sciences Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres to Liver Tumors using Pressure-Enabled Drug Delivery (PEDD) via the TriNav Infusion System (Business Wire)
Jan-08-25 08:00AM	TriSalus Announces Leadership Changes (Business Wire) -7.18%
Nov-14-24 08:00AM	TriSalus Reports Q3 2024 Financial Results and Provides Business Update (Business Wire) -10.89%
Nov-13-24 07:27AM	TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-11-24 07:00AM	TriSalus Life Sciences Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav Infusion System to U.S. Veterans with Liver Cancer (Business Wire) +5.91%
Nov-07-24 07:00AM	TriSalus Life Sciences Launches TriNav LV Infusion System and TriGuide Guiding Catheters, Expanding Portfolio of PEDD Devices for Improved Tumor Treatment (Business Wire)
Oct-31-24 08:00AM	TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call (Business Wire)
Oct-14-24 04:05PM	TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-26-24 07:00AM	TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board (Business Wire)
Sep-23-24 07:00AM	TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD Method via the TriNav Infusion System (Business Wire) -6.70%
Sep-14-24 01:52AM	TriSalus Life Sciences Inc (TLSI) CEO Buys Shares (GuruFocus.com)
Aug-15-24 08:00AM	TriSalus Reports Q2 2024 Financial Results and Business Update (Business Wire)
Aug-01-24 07:00AM	TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call (Business Wire)
Jul-01-24 04:00PM	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation (Business Wire) -5.07%
Jun-26-24 05:45PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire)
Jun-03-24 07:00AM	TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting (Business Wire)
May-24-24 06:05AM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire) -20.75%
May-15-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.49%
08:00AM	TriSalus Reports Q1 2024 Financial Results and Business Update (Business Wire)
May-07-24 07:00AM	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors (Business Wire)
May-06-24 04:58PM	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call (Business Wire)
Apr-30-24 04:35PM	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives (Business Wire)
Apr-01-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.13%
09:33AM	TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ... (GuruFocus.com)
08:00AM	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-26-24 08:00AM	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Mar-21-24 08:00AM	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting (Business Wire)
Mar-11-24 05:15PM	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results (Business Wire)
Mar-07-24 07:00AM	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Associations Adopted Name Council for Nelitolimod as the Nonproprietary Drug Name for SD-101 (Business Wire)
Feb-29-24 07:00AM	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors (Business Wire)
Dec-14-23 07:00AM	TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code (Business Wire) +33.61%
Nov-14-23 12:27PM	TriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023 (GuruFocus.com)
08:00AM	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-07-23 04:05PM	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call (Business Wire) -5.39%
Nov-04-23 02:25PM	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications (Business Wire)
Nov-03-23 12:00PM	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Business Wire) +12.90%
Oct-25-23 09:05AM	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Business Wire)
Sep-06-23 07:00AM	TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics (Business Wire) -6.96%
Aug-10-23 04:05PM	TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation (Business Wire) +18.67% +5.82%
Aug-02-23 05:00PM	MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders (Business Wire) -5.60%
Jun-12-23 07:00AM	TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting (Business Wire)
Apr-20-23 07:00AM	TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients With Liver Metastases (Business Wire)
Feb-21-23 07:00AM	TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business (Business Wire)
Dec-07-22 09:26PM	MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders (GlobeNewswire)
Nov-14-22 04:24PM	Colorado biotech company to go public via SPAC merger (American City Business Journals)
Mar-14-22 02:32PM	Robotic surgery company Memic pulls out of SPAC merger (American City Business Journals)
Mar-10-22 08:11AM	MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination (GlobeNewswire)
Jan-06-22 08:00AM	Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021 (PR Newswire)
Dec-30-21 03:00PM	A look at the South Florida tech companies that were acquired or went public in 2021 (American City Business Journals)
Oct-07-21 09:16AM	Is MedTech Acquisition Corporation (NASDAQ:MTAC) Popular Amongst Institutions? (Simply Wall St.)

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cox Bryan F.	Chief of Research	May 19 '25	Sale	5.18	4,764	24,678	119,415	May 21 05:33 PM
Devlin Jodi	Chief of Clinical Operations	May 19 '25	Sale	5.18	4,764	24,678	52,764	May 21 05:31 PM
Marshak Richard	Chief Commercial Officer	May 19 '25	Sale	5.18	6,597	34,172	69,101	May 21 05:30 PM
Stevens Jennifer	Chief Regulatory Officer	May 19 '25	Sale	5.18	8,704	45,087	77,640	May 21 05:27 PM

CHRS

Coherus Oncology Inc

TLSI

TriSalus Life Sciences Inc

Upgrade your FINVIZ experience